Article and Video CATEGORIES
David Gray has been involved in clinical drug development in the pharmaceutical and biotechnology industries for over twenty-five years including leadership positions in clinical operations and biostatistics. He feels fortunate to have participated in the development and approval of life-changing therapies including an aerosol antibiotic for cystic fibrosis and a targeted antibody drug conjugate for Hodgkin and T-cell lymphomas.
GRACE is celebrating 10 years!
In recognition, we would like to introduce you to the staff and board members who are so deeply involved in bringing GRACE to life. In this video, we introduce David Gray.
Dr. H. Jack West and the GRACE community have been helping each other since before that time but in this 10th year as a non-profit, we are pleased and humbled by the feedback and graciousness of those we have the pleasure to work with, and those who have found help and support through our GRACE site.
We are more than pleased to be able to continue our mission to provide expert-mediated information on current and emerging cancer management options in order to empower patients, caregivers, and health professionals to become direct partners in cancer care. https://cancerGRACE.org/
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…
That's just beautiful Linda. Thank you,